

Original article

Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel



Sergio Raposeiras-Roubín,^a Emad Abu-Assi,^{a,*} Fabrizio D'Ascenzo,^b Saleta Fernández-Barbeira,^a Tim Kinnaird,^c Albert Ariza-Solé,^d Sergio Manzano-Fernández,^e Christian Templin,^f Lazar Velicki,^{g,h} Ioanna Xanthopoulou,ⁱ Enrico Cerrato,^j Giorgio Quadri,^k Andrea Rognoni,^l Giacomo Boccuzzi,^m Andrea Montabone,^m Salma Taha,ⁿ Alessandro Durante,^o Sebastiano Gili,^f Giulia Magnani,^f Michele Autelli,^b Alberto Grosso,^b Pedro Flores Blanco,^e Alberto Garay,^d Ferdinando Varbella,^k Francesco Tommassini,^k Berenice Caneiro Queija,^a Rafael Cobas Paz,^a María Cespón Fernández,^a Isabel Muñoz Pousa,^a Diego Gallo,^p Umberto Morbiducci,^p Alberto Domínguez-Rodríguez,^q José Antonio Baz-Alonso,^a Mariano Valdés,^e Ángel Cequier,^d Fiorenzo Gaita,^b Dimitrios Alexopoulos,ⁱ and Andrés Íñiguez-Romo^a

^a Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, Spain

^b Department of Cardiology, Department of Medical Sciences, University of Torino, Torino, Italy

^c Cardiology Department, University Hospital of Wales, Cardiff, Wales, United Kingdom

^d Servicio de Cardiología, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

^e Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain

^f Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland

^g Medical Faculty, University of Novi Sad, Novi Sad, Serbia

^h Institute of Cardiovascular Diseases Voivodina, Sremska Kamenica, Serbia

ⁱ University Patras Hospital, Atenas, Rion, Patras, Greece

^j Department of Cardiology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy

^k Department of Cardiology, Infermi Hospital, Rivoli, Italy

^l Coronary Care Unit and Catheterization Laboratory, A.O.U. Maggiore della Carità, Novara, Italy

^m Department of Cardiology, S.G. Bosco Hospital, Turin, Italy

ⁿ Department of Cardiology, Faculty of Medicine, Assiut University, Assiut, Egypt

^o Unità Operativa di Cardiologia, Ospedale Valduce, Como, Italy

^p PolitoBIOMed Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy

^q Servicio de Cardiología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

Article history:

Received 27 August 2017

Accepted 28 February 2018

Available online 25 June 2018

Keywords:

Ticagrelor

Prasugrel

Stent thrombosis

Acute coronary syndrome

ABSTRACT

Introduction and objectives: There is little evidence on rates of stent thrombosis (ST) in patients receiving dual antiplatelet therapy (DAPT) with ticagrelor or prasugrel. The aim of this study was to analyze the incidence and predictors of ST after an acute coronary syndrome among patients receiving DAPT with ticagrelor vs prasugrel.

Methods: We used data from the RENAMI registry (Registry of New Antiplatelet therapy in patients with acute Myocardial Infarction), analyzing a total of 4123 acute coronary syndrome patients discharged with DAPT with ticagrelor or prasugrel in 11 centers in 6 European countries. The endpoint was definite ST within the first year. A competitive risk analysis was carried out using a Fine and Gray regression model, with death being the competitive event.

Results: A total of 2604 patients received DAPT with ticagrelor and 1519 with prasugrel; ST occurred in 41 patients (1.10%), with a similar cumulative incidence between ticagrelor (1.21%) and prasugrel (0.90%). The independent predictors of ST were age (sHR, 1.03; 95%CI, 1.01-1.06), ST segment elevation (sHR, 2.24; 95%CI, 1.22-4.14), previous myocardial infarction (sHR, 2.56; 95%CI, 1.19-5.49), and serum creatinine (sHR, 1.29; 95%CI, 1.08-1.54).

Conclusions: Stent thrombosis is infrequent in patients receiving DAPT with ticagrelor or prasugrel. The variables associated with an increased risk of ST were advanced age, ST segment elevation, previous myocardial infarction, and serum creatinine.

© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author: Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Clara Campoamor 341, 36212 Vigo, Pontevedra, Spain.
E-mail address: eabuassi@gmail.com (E. Abu-Assi).

Incidencia anual de trombosis del *stent* confirmadas y factores clínicos predictores en pacientes con SCA tratados con ticagrelor o prasugrel

RESUMEN

Palabras clave:

Ticagrelor
Prasugrel
Trombosis del *stent*
Síndrome coronario agudo

Introducción y objetivos: Hay muy poca evidencia sobre las tasas de trombosis del *stent* (TS) en pacientes que reciben tratamiento antiagregante plaquetario doble (TAPD) con ticagrelor o prasugrel. El objetivo de este estudio es analizar la incidencia y predictores de la TS tras un síndrome coronario agudo en pacientes que reciben TAPD con ticagrelor frente a prasugrel.

Métodos: Se utilizaron datos del registro RENAMI (*REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction*), y se analizó en total a 4.123 pacientes con síndrome coronario agudo dados de alta con TAPD con ticagrelor o prasugrel en 11 centros de 6 países europeos. Se consideró como evento la TS confirmada en el primer año. Se realizó un análisis de riesgos competitivos mediante un modelo de regresión de Fine y Gray, siendo la muerte el evento competitivo.

Resultados: Recibieron TAPD con ticagrelor 2.604 pacientes y con prasugrel, 1.519; 41 pacientes (1,10%) presentaron TS, con incidencias acumuladas similares entre ticagrelor (1,21%) y prasugrel (0,90%). Los predictores independientes de la TS fueron: la edad (sHR = 1,03; IC95%, 1,01-1,06), la elevación del segmento ST (sHR = 2,24; IC95%, 1,22-4,14), el antecedente de infarto de miocardio (sHR = 2,56; IC95%, 1,19-5,49) y la creatinina sérica (sHR = 1,29; IC95%, 1,08-1,54).

Conclusiones: La TS es infrecuente en pacientes que reciben TAPD con ticagrelor y prasugrel. La edad avanzada, la elevación del segmento ST, el antecedente de infarto y la creatinina sérica son las variables que se asocian con mayor riesgo de TS.

© 2018 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Abbreviations

ACS: acute coronary syndrome
AMI: acute myocardial infarction
DAPT: dual antiplatelet therapy
DES: drug-eluting stent
PCI: percutaneous coronary intervention
ST: stent thrombosis

INTRODUCTION

Because patients with acute coronary syndrome (ACS) have excessive platelet reactivity, antiplatelet therapy is vital to prevent new ischemic events.¹ New antiplatelet agents such as prasugrel and ticagrelor have been developed in recent years. Both drugs show greater ability than clopidogrel to reduce stent thrombosis (ST).^{2,3} However, the available data on the impact of prasugrel and ticagrelor on ST events are mainly derived from clinical trials, and little patient information is available from clinical practice. In addition, few studies have compared the therapeutic benefit, in terms of ST rates, between prasugrel and ticagrelor.⁴⁻⁷

The aim of this study was to evaluate, from a descriptive-analytical point of view, the incidence and predictors of ST in patients with ACS receiving dual antiplatelet therapy (DAPT) with aspirin plus prasugrel or ticagrelor using data from an international registry of patients undergoing percutaneous coronary revascularization.

METHODS

Study Population

The RENAMI (*REgistry of New Antiplatelet therapy in patients with Myocardial Infarction*) is a retrospective, observational, multicenter, and international registry involving the voluntary participation of 11 centers from 6 European countries (Spain, Italy, Switzerland, Greece, Serbia, and the United Kingdom). The objective of this unfunded registry is to improve our understanding

of ischemic and hemorrhagic complications in patients with ACS treated with DAPT with prasugrel or ticagrelor. All participating centers are third-level university hospitals with a 24-hour catheterization laboratory and internal medical records on ACS. From January 2012 to January 2016, each participating center consecutively enrolled patients with ACS and coronary stenosis $\geq 50\%$ in the left main coronary artery and $\geq 70\%$ in the rest of the coronary tree who underwent percutaneous coronary intervention (PCI). Additionally, these patients were discharged with DAPT comprising aspirin (100 mg/24 h) plus prasugrel (10 mg/24 h) or aspirin (100 mg/24 h) plus ticagrelor (90 mg/12 h). The design of the RENAMI registry and the inclusion and exclusion criteria are described in detail in the supplementary material. The variables included in the RENAMI registry are listed in [Table 1 of the supplementary material](#) and the participating centers in [Table 2 of the supplementary material](#). The ACS was defined as ST-segment elevation myocardial infarction (STEMI), non-STEMI, and unstable angina according to the definitions accepted in clinical practice guidelines.⁸⁻¹⁰ Acute myocardial infarction (AMI) was diagnosed according to the universal definition of AMI.¹¹ Unstable angina was diagnosed through the presence of its classic symptoms or objective evidence of myocardial ischemia in a stress test, together with detection of a culprit lesion on coronary angiography.

For the purpose of RENAMI, a database was designed to retrospectively include information on clinical, analytical, and angiographic variables, as well as data related to mortality and ischemic and hemorrhagic events. RENAMI registry analyses were carried out by 2 researchers from the coordination center (E. Abu-Assi and S. Raposeiras-Roubín). All procedures were performed according to the provisions of the Declaration of Helsinki and with the approval of the local ethics committees.

Of the 4424 patients in the RENAMI registry, the present study excluded those with no information on the type of stent implanted (n = 297) and those with a first-generation drug-eluting stent (DES) (n = 4). Thus, the final study cohort comprised 4123 patients.

Endpoint, Definitions, and Follow-up

The study endpoint was ST in patients receiving DAPT with ticagrelor or prasugrel, considering only thrombosis confirmed according to the definition of the Academic Research Consortium

(angiographic or pathologic confirmation).¹² STs were classified as early (occurring in the first month after PCI) or late (occurring between 1 and 12 months after PCI). In addition, early STs were subdivided into acute (first 24 hours) and subacute (between 1 and 30 days). Stent thromboses occurring in the acute phase before the administration of prasugrel or ticagrelor (in the case of patients initially treated with DAPT with clopidogrel) were excluded from the event file because the objective was to study the ST rates of patients on DAPT with ticagrelor or prasugrel. Follow-up was censored at ST occurrence (n = 41), death (n = 72), DAPT suspension/withdrawal within 1 year after the PCI (n = 382), or at 12 months of follow-up.

Analysis of the composite endpoint of death and/or ST is shown in [Table 3 of the supplementary material](#). This secondary analysis was performed due to the small number of ST events.

Data on vital status (alive or dead) and event (ST) were obtained from hospital clinical data records and administrative records (vital statistics records, hospital discharge data, and emergency department data). When information was missing, patients or their relatives or primary care physicians were contacted by telephone.

According to a report of the European Society of Cardiology and the European Association of PCI,¹³ all stents succeeding the first-generation stents were considered new-generation DESs; the first-generation stents were the sirolimus-eluting CYPHER, paclitaxel-eluting TAXUS, and zotarolimus-eluting Endeavor. Thus, “new-generation DESs” refer to the everolimus-eluting XIENCE V (Abbott Vascular, Illinois, United States) and Promus (Boston-Scientific, Massachusetts, United States), zotarolimus-eluting Resolute (Medtronic; Minnesota, United States), sirolimus-eluting Yukon DES (Translumina GmbH; Hechingen, Germany), and biolimus-eluting Nobori (Terumo, Japan) and Biomatrix (Biosensors, Singapore). Bioabsorbable stents were also considered new-generation DESs.

Statistical Analysis

Continuous variables are presented as mean ± standard deviation. Discrete variables are expressed as percentages. Continuous variables were compared with the Student *t* test and discrete variables with the chi-square test or Fisher exact test, as necessary.

To study ST predictors, a competing risk analysis was performed with a Fine and Gray regression model,¹⁴ with death considered the competing event. All variables associated ($P < .10$) with ST in univariable analysis were included in a multivariable model. There was no evidence of noncompliance with the proportional hazards assumption, verified by studying the interaction of covariables in the models with time: in the absence of statistical significance ($P > .05$), it can be deduced that the proportional hazards assumption has not been violated. To account for the potential heterogeneity arising from the inclusion of centers from different European countries, an interaction term was included in the final model through a nonhierarchical grouping analysis by group (country). The predictive accuracy of the final model was calculated via the C-statistic, using the *c-index* function of the “pec” extension for R. Results are expressed as the subhazard ratio (sHR) with its corresponding 95% confidence interval (95%CI).

Cumulative incidence function curves were plotted for ticagrelor and prasugrel after estimation of the cumulative incidence function curve using a flexible parametric model for competing risks,¹⁵ adjusted for the variables associated ($P < .10$) in the univariable analysis with a higher incidence of ST ([Table 1](#)): age, previous myocardial infarction, STEMI presentation, left ventricular ejection fraction < 40%, and serum creatinine.

The composite analysis of death and ST ([Figure of the supplementary material](#)) was performed using a Cox model;

Table 1

Baseline Characteristics of the Study Population According to Whether the Dual Antiplatelet Therapy Involved Ticagrelor or Prasugrel

Variable	Ticagrelor (n = 2604)	Prasugrel (n = 1519)	P
Age, y	62.3 ± 11.9	59.0 ± 10.6	< .001
Women	24.2	16.3	< .001
BMI	27.1 ± 4.2	28.1 ± 3.9	< .001
Hypertension	56.5	50.3	< .001
Diabetes mellitus	31.8	27.8	.008
Dyslipidemia	55.2	51.6	.029
Active smoking	21.9	37.0	< .001
Previous AMI	18.5	14.3	< .001
Unstable angina	10.9	7.7	.001
STEMI	48.5	70.7	< .001
Killip ≥ II	7.3	14.7	< .001
LVEF < 40%	7.4	10.9	< .001
Hemoglobin, g/dL	14.2 ± 1.2	14.1 ± 1.3	< .001
Serum creatinine, mg/dL	1.0 ± 0.5	0.9 ± 0.4	.080
Multivessel disease	47.4	42.6	.011
Glycoprotein IIb/IIIa inhibitors	16.2	25.1	< .001

AMI, acute myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation acute myocardial infarction. Values are expressed as percentage or mean ± standard deviation.

ticagrelor and prasugrel curves were compared by a log-rank test and the restricted mean survival time method.¹⁶

Statistical analyses were performed with Stata 13.1 and R version 3.3.1. $P < .05$ was considered statistically significant.

RESULTS

Study Population Characteristics

The clinical characteristics of the study population are shown in [Table 1](#) according to use of ticagrelor and prasugrel. The 2 drugs clearly display different prescription patterns.

Regarding DAPT, 63.2% of patients (n = 2604) received ticagrelor and 36.8% (n = 1519) received prasugrel. The mean follow-up time was 10.9 ± 2.9 months; 82.9% of patients completed 12 months of follow-up with DAPT (94.4% > 6 months, 88.4% > 9 months).

Bare-metal stents were used in 29.2% of the patients (n = 1205) and new-generation DESs in the remaining 70.8% (n = 2918). Only 4.0% of patients treated with DESs received bioabsorbable stents (n = 117): 24.8% received zotarolimus-eluting stents; 24.4%, everolimus-eluting; 12.8%, biolimus-eluting; and 3.1%, sirolimus-eluting. The remaining 30.9% received new-generation DESs (nonbioabsorbable) but the type was not specified.

Stent Thrombosis Incidence

Of the 4123 patients with ACS treated with DAPT with ticagrelor and/or prasugrel, 41 experienced ST in the first year (1.10/100 person-years, 95%CI, 0.81–1.49) ([Figure 1](#)); 58.6% of the STs were early, occurring in the first month (36.6% in the first 24 h and 22.0% between the first day and the first month), whereas 41.5% were late, occurring between the first month and the first year.

Regarding stent type, there were no significant differences in the cumulative incidences of ST between bare-metal stents (0.83%; 95%CI, 0.43–1.60) and new-generation DESs (1.20%; 95%CI,




Figure 1. Cumulative incidence of ST in the first year in patients with acute coronary syndrome on DAPT with aspirin plus prasugrel or ticagrelor. 95%CI, 95% confidence interval; DAPT, dual antiplatelet therapy; ST, stent thrombosis.

0.85-1.70). Bioabsorbable stents were implanted in 127 patients; of these, only 1 experienced a ST in the first year.

Stent Thrombosis Predictors

The association between the clinical variables analyzed and a higher incidence of ST in the first year in the univariable analysis is shown in Table 2. Multivariable analysis identified the following independent predictors of ST in the first year: age, STEMI presentation, previous AMI, and serum creatinine (Table 3). The discriminative ability of the final model was good, with a C-statistic of 0.70. The same variables were significant in the univariable analysis if it was limited to ST in the first month (Table 2). However, after multivariable adjustment, the only independent predictors of early ST were age, STEMI presentation, and serum creatinine (Table 3).

Relationship Between Stent Thrombosis and Antiplatelet Therapy Type

The cumulative incidence of ST occurring in the first year was 1.21% (95%CI, 0.53-1.56) with ticagrelor and 0.90% (95%CI, 0.84-1.76)

with prasugrel. There were no significant differences between the 2 drugs regarding the risk of ST in the first year (ticagrelor vs prasugrel, sHR = 1.29; 95%CI, 0.67-2.45; P = .445). The adjusted curves of the cumulative incidence of ST estimated with ticagrelor and prasugrel in the first year are shown in Figure 2. There were also no significant differences between ticagrelor and prasugrel in terms of ST in the first month (0.7% vs 0.4%; P = .144).

No associations were found for ST risk with ticagrelor vs prasugrel, bare-metal stents (ticagrelor vs prasugrel, sHR = 1.40; 95%CI, 0.35-5.56; P = .635), or new-generation DESs (sHR = 1.23; 95%CI, 0.58-2.58; P = .587).

DISCUSSION

The most interesting findings of this study can be summarized in 4 points: a) the incidence of ST in patients with ACS on DAPT with ticagrelor or prasugrel is low, and the risk is highest in the first month; b) age, previous infarction, STEMI presentation, and renal function are the main predictors of ST in patients treated with ticagrelor or prasugrel; c) in patients who received DAPT with ticagrelor or prasugrel, no differences in ST risk were found between bare-metal stents and new-generation DESs; and d) in general, there was no difference between prasugrel and ticagrelor regarding the risk of ST in the first year, although higher-powered studies are needed to accurately compare the 2 drugs in this regard.

The annual incidence of ST is highly variable and highly dependent on the interaction of different factors, such as the study population (with or without ACS), type of antiplatelet agent used (clopidogrel or the new P2Y₁₂ inhibitors), and type of stent (bare-metal stents, first-generation DESs, new-generation DESs, bioabsorbable DESs).¹⁷⁻¹⁹ Thus, the first-year ST incidence in the literature ranges from 0.5% to 1.5%, with between 50% and 70% occurring in the first month,^{20,21} data that are similar to ours. The present study focuses on a contemporary population of patients with ACS (more than 50% with STEMI), all treated with DAPT with ticagrelor (63.2%) or prasugrel (36.8%) and implanted with either a bare-metal stent (29.2%) or new-generation DES (70.8%). In this population context, the incidences of ST are reported in patients with ongoing DAPT (because the termination of this therapy was a motive for censoring of follow-up, as explained in the “Methods”),

Table 2
Univariable Analysis of Stent Thrombosis in the First Year and in the First Month

Variable	ST in the first year			ST in the first month		
	sHR	95%CI	P	sHR	95%CI	P
Age	1.04	1.01-1.06	.002	1.05	1.01-1.08	.009
Female sex	1.20	0.64-2.24	.564	.97	0.67-1.42	.882
Hypertension	1.32	0.53-3.25	.548	0.84	0.51-1.41	.515
Diabetes mellitus	1.05	0.49-2.27	.890	1.15	0.33-4.01	.827
Dyslipidemia	1.48	0.74-2.96	.269	1.01	0.53-1.93	.968
Active smoking	1.21	0.81-1.48	.351	0.97	0.68-1.39	.877
Previous AMI	2.84	1.25-6.44	.013	2.02	1.02-4.02	.044
STEMI	1.86	1.02-3.39	.042	1.86	1.02-3.29	.033
LVEF < 40%	3.04	1.15-8.02	.025	2.48	0.98-6.25	.054
Hemoglobin	1.01	0.87-1.18	.862	1.01	0.77-1.32	.959
Creatinine	1.33	1.17-1.52	<.001	1.41	1.25-1.59	<.001
Multivessel disease	0.61	0.32-1.17	.137	0.59	0.25-1.43	.247
Glycoprotein IIb/IIIa inhibitors	1.61	0.63-4.11	.315	0.98	0.44-2.19	.967
Ticagrelor vs prasugrel	1.28	0.67-2.45	.445	1.76	0.98-3.16	.061
New-generation DESs vs BMSs	1.48	0.23-9.57	.678	2.89	0.40-20.98	.293

95%CI, 95% confidence interval; AMI, acute myocardial infarction; BMS, bare-metal stent; DES, drug-eluting stent; LVEF, left ventricular ejection fraction; sHR, subhazard ratio; STEMI, ST-segment elevation acute myocardial infarction; ST, stent thrombosis.

Table 3

Multivariable Analysis for Predicting Stent Thrombosis in the First Year and Particularly in the First Month

Variables	sHR	95%CI	P
<i>Stent thrombosis in the first year</i>			
Age, for each 1 year increment	1.03	1.01-1.06	.009
Previous AMI	2.56	1.19-5.49	.016
STEMI	2.24	1.22-4.14	.010
LVEF < 40%	2.07	0.92-4.65	.079
Creatinine, for each 1 mg/dL increment	1.29	1.08-1.54	.005
Ticagrelor vs prasugrel	1.12	0.60-2.10	.729
<i>Stent thrombosis in the first month</i>			
Age, for each 1 year increment	1.04	1.00-1.08	.028
Previous AMI	1.74	0.85-3.54	.130
STEMI	2.42	1.48-3.95	<.001
LVEF < 40%	1.20	0.74-3.42	.232
Creatinine, for each 1 mg/dL increment	1.42	1.21-1.65	<.001
Ticagrelor vs prasugrel	1.53	0.86-2.72	.144

95%CI, 95% confidence interval; AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; sHR, subhazard ratio; STEMI, ST-segment elevation myocardial infarction.

which is one of the strengths of this study. This is particularly interesting because it presents an ideal scenario to mitigate ST: treatment with stents other than first-generation DESs and DAPT with new and more potent inhibitors of P2Y₁₂. This population group showed a cumulative incidence of ST in the first year of 1.1% (0.6% in the first month), despite comprising patients on DAPT with ticagrelor or prasugrel. This rate reflects the complex pathophysiology of ST due to the involvement of multiple interrelated factors, in addition to the DAPT itself. Indeed, in the PESTO (Morphological Parameters Explaining Stent Thrombosis) registry, a mechanical abnormality of the implanted stent was observed on optical coherence tomography in 97% of patients with ST.²² Recently, a study by Cuesta et al.²³ also showed through optical coherence tomography that the predominant mechanism in 39% of early ST was stent malapposition.

Independent predictors of ST in patients treated with DAPT with ticagrelor or prasugrel were persistent ST-segment elevation, previous AMI, and renal failure. These factors were also identified in other studies and reflect situations of greater thrombogenicity (STEMI, recurrent AMI, ventricular dysfunction) and coagulopathy (age, renal failure).^{24–27}




Figure 2. Cumulative incidence of ST estimated according to the type of antiplatelet agent, after adjustment for age, previous myocardial infarction, presentation as ST-segment elevation acute myocardial infarction, left ventricular ejection fraction < 40%, and serum creatinine. 95%CI, 95% confidence interval; CIF, cumulative incidence function curve; DAPT, dual antiplatelet therapy; ST, stent thrombosis.

Both ticagrelor and prasugrel were associated with a marked reduction in ST vs clopidogrel in the pivotal clinical trials. The PLATO study showed a 33% reduction in the 1-year incidence of definite ST with ticagrelor vs clopidogrel (1.93% vs 1.37%, hazard ratio [HR] = 0.67; 95%CI, 0.50-0.90; $P = .009$),² which was later confirmed in the SWEDEHEART registry.²⁸ In the TRITON study, the 15-month incidence of definite ST was 2.2% in the clopidogrel group but 1.1% in the prasugrel group.³ Regarding the “real life” population, that is, beyond patients included in clinical trials, only indirect data have been available from a limited number of registries.^{4–7} In our study, no significant differences were found between the 2 drugs (ticagrelor and prasugrel) in the cumulative incidence of ST at 1 year (1.2% with ticagrelor, 0.9% with prasugrel) or at 30 days (0.7% with ticagrelor, 0.4% with prasugrel). Although there has been little evidence of the true incidence of ST with prasugrel and ticagrelor in the setting of an ACS, the data obtained agree with those published in the most recent studies. In the PRAGUE study,⁶ in the setting of STEMI, the 1-month incidences of definite ST were 0.9% with ticagrelor and 0.5% with prasugrel; this difference was also not statistically significant but was limited by the small sample size (634 patients with prasugrel and 596 with ticagrelor). Previously, Larmore et al.⁵ published data from an American registry of patients with ACS with a considerable sample size (13 134 patients with prasugrel and 2964 with ticagrelor). The authors observed 30-day ST rates of 0.7% with ticagrelor and 0.3% with prasugrel, with a significant association in favor of prasugrel in the univariable analysis, although the benefit was diluted after propensity score matching (relative risk = 0.56; 95%CI, 0.26-1.20; $P = .131$). Therefore, given the concordance of the data among the different studies, it seems reasonable to ask whether the absence of a significant difference between ticagrelor and prasugrel for ST is due to a power problem in the different studies (in order for a difference such as that obtained to be significant with an ST incidence similar to the one reported here, the sample size would have to exceed 14 000 patients with 95% CI and 80% power) or differences in baseline characteristics between patients treated with ticagrelor and prasugrel. This supposition leads to an interesting working hypothesis for future studies, with a view to determining whether prasugrel vs ticagrelor actually reduces the risk of ST, especially that of early ST. Although this greatly depends on procedural variables, residual platelet reactivity despite treatment has been associated with a marked increase in the risk of early ST. In fact, the factor that is alone associated with an increased risk of early ST is absence of platelet P2Y₁₂ receptor inhibition.²⁹ However, because the comparisons between the 2 drugs in terms of platelet inhibition were similar, and even better with ticagrelor,^{30–33} the results are difficult to understand from a pharmacodynamic point of view.

Regarding stent type, no differences were found in this study between ticagrelor and prasugrel in the ST rates of patients treated with bare-metal stents or new-generation DESs. Current evidence comparing the 2 types of stent shows equivalent results or even favorable results for new-generation DESs in terms of thrombogenicity.^{34,35} However, the findings are based on a population that generally received DAPT with clopidogrel, whose platelet inhibition is slower and more variable than that of ticagrelor and prasugrel. The more biocompatible polymer coatings of the new DESs have been suggested to reduce the thrombogenicity associated with the interaction between the stent and the blood,³⁶ but little is known about the interaction between the type of stent and the type of antiplatelet agent. Thus, this study provides new information by revealing the ST rates in patients on DAPT with ticagrelor or prasugrel according to type of stent (bare-metal or new-generation DES). No significant differences were found in our registry between bare-metal stents and new-generation DESs, although the study was not designed for that purpose.

Limitations

The 2 main limitations of this study lie in its retrospective design and in the sample size. The study suffers from the same limitations as other retrospective studies. Specifically, because it is not randomized and ticagrelor and prasugrel use are at the discretion of the treating physician, comparisons between these drugs or between bare-metal stents and DESs should be interpreted with caution due to the possible interaction of unmeasured confounding variables. For example, RENAMI does not provide information on angiographic characteristics possibly critically involved, particularly in early ST, such as TIMI (Thrombolysis In Myocardial Infarction) flow after PCI, stent diameter/length, residual untreated coronary dissection, and high residual thrombotic load. There is also no information on how many patients underwent intracoronary imaging after PCI to verify proper stent expansion. In addition, the sample size of the study, with 4123 patients, is insufficient to reach robust conclusions due to the low frequency of the study event (ie, ST), as already mentioned. However, given the high lethality posed by ST and the limited scientific evidence available on this event in patients on DAPT with ticagrelor or prasugrel, the present study—even with a more descriptive than analytical approach—has scientific value in hypothesis generation for subsequent scientific studies (clinical trials or meta-analyses).

CONCLUSIONS

ST was infrequent in patients on DAPT with ticagrelor or prasugrel. Four independent predictors were associated with higher ST risk: previous infarction, STEMI presentation, age, and serum creatinine. Antiplatelet agent and stent type were not associated with an increased risk of ST in the present study. Designs with higher power are required for comparative studies of the ability of prasugrel and ticagrelor to protect against ST.

CONFLICTS OF INTEREST

E. Abu-Assi is an Associate Editor of *Revista Española de Cardiología*.

WHAT IS KNOWN ABOUT THE TOPIC?

- Stent thrombosis is a dreaded complication after percutaneous coronary revascularization due to its high lethality. However, its incidence is currently low with the use of bare-metal stents and new-generation DESs. In addition, a reduced ST rate has been found with both ticagrelor and prasugrel vs clopidogrel.

WHAT DOES THIS STUDY ADD?

- Beyond the pivotal clinical trials (PLATO and TRITON-TIMI), little is known about the incidence and predictors of ST in patients receiving DAPT with ticagrelor or prasugrel. This study analyzes both the incidence and predictors of ST after ACS in patients on DAPT with aspirin plus ticagrelor or aspirin plus prasugrel after percutaneous revascularization with bare-metal stents or new-generation DESs.

SUPPLEMENTARY MATERIAL



Supplementary material associated with this article can be found in the online version available at <https://doi.org/10.1016/j.rec.2018.05.021>.

REFERENCES

1. De la Torre Hernandez JM, Oteo Dominguez JF, Hernandez F, et al. Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2. *Rev Esp Cardiol*. 2015;68:838–845.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045–1057.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001–2015.
4. Almendro-Delia M, García-Alcántara A, De la Torre-Prados MV, et al. Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. Results of a “Real World” Multicenter Registry. *Rev Esp Cardiol*. 2017;70:952–959.
5. Larmore C, Effron MB, Molife C, et al. Real-world” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. *Catheter Cardiovasc Interv*. 2016;88:535–544.
6. Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study. *Circulation*. 2016;134:1603–1612.
7. Zeymer U, Widimsky P, Danchin N, et al. P2Y₁₂ receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. *Eur Heart J Cardiovasc Pharmacother*. 2016;2:229–243.
8. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018;39:119–177.
9. SEC Working Group for the 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation, Expert Reviewers for the 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation, and the SEC Guidelines Committee. Comments on the 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation. *Rev Esp Cardiol*. 2017;70:1039–1045.
10. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. *Rev Esp Cardiol*. 2015;68:1125.
11. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Circulation*. 2012;126:2020–2035.
12. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation*. 2007;115:2344–2351.
13. Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. *Eur Heart J*. 2015;36:2608–2620.
14. Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94:496–509.
15. Lambert PC. A flexible parametric competing-risks model using a direct likelihood approach for the cause-specific cumulative incidence function. *Stata J*. 2017;17:462–489.
16. Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. *Biometrics*. 2016;72:215–221.
17. Wiebe J, Hoppmann P, Colleran R, et al. Long-term clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine practice: 2-year results of the ISAR-ABSORB Registry. *JACC Cardiovasc Interv*. 2017;10:1222–1229.
18. Shah R, Ramos-Bondy B, Mizeracki A. Risk of stent thrombosis with bioresorbable vascular scaffolds. *Lancet*. 2016;387:1903.
19. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. *Eur Heart J*. 2015;36:3320–3331.
20. Ge J, Yu H, Li J. Acute coronary stent thrombosis in modern era: etiology, treatment, and prognosis. *Cardiology*. 2017;137:246–255.
21. Sarno G, Lagerqvist B, Frobert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). *Eur Heart J*. 2012;33:606–613.
22. Souteyrand G, Amabile N, Mangin L, et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. *Eur Heart J*. 2016;37:1208–1216.
23. Cuesta J, Rivero F, Bastante T, et al. Optical Coherence Tomography Findings in Patients With Stent Thrombosis. *Rev Esp Cardiol*. 2017;70:1050–1058.

24. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. *Circulation*. 2011;123:1745–1756.
25. Malik N, Banning AS, Belger M, et al. A risk scoring system to predict coronary stent thrombosis. *Curr Med Res Opin*. 2017;33:859–867.
26. Baran KW, Lasala JM, Cox DA, et al. A clinical risk score for prediction of stent thrombosis. *Am J Cardiol*. 2008;102:541–545.
27. Dangas GD, Claessen BE, Mehran R, et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. *JACC Cardiovasc Interv*. 2012;5:1097–1105.
28. Sahlen A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. *Eur Heart J*. 2016;37:3335–3342.
29. Van Werkum JW, Heestermaas AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. *J Am Coll Cardiol*. 2009;53:1399–1409.
30. Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. *J Thromb Haemost*. 2015;13:931–942.
31. Bernlochner I, Mayer K, Orban M, et al. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. *Platelets*. 2016;27:796–804.
32. Franchi F, Rollini F, Aggarwal N, et al. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: The OPTIMUS-4 Study. *Circulation*. 2016;134:780–792.
33. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID primary PCI study. *J Am Coll Cardiol*. 2013;61:1601–1606.
34. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. *Lancet*. 2012;379:1393–1402.
35. De la Torre Hernández JM, Alfonso F, Gimeno F, et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2. *JACC Cardiovasc Interv*. 2010;3:911–919.
36. Sarno G, Lagerqvist B, Nilsson J, et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. *J Am Coll Cardiol*. 2014;64:16–24.